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Background: Abnormal tau hyperphosphorylation and its accumulation into intra-neuronal neurofibrillary tangles
are linked to neurodegeneration in Alzheimer’s disease and similar tauopathies. One strategy to reduce accumulation is
through immunization, but the most immunogenic tau epitopes have so far remained unknown. To fill this gap, we
immunized mice with recombinant tau to build a map of the most immunogenic tau epitopes.
Methods: Non-transgenic and rTg4510 tau transgenic mice aged 5 months were immunized with either human wild-type
tau (Wt, 4R0N) or P301L tau (4R0N). Each protein was formulated in Quil A adjuvant. Sera and splenocytes of vaccinated
mice were collected to assess the humoral and cellular immune responses to tau. We employed a peptide array assay to
identify the most effective epitopes. Brain histology was utilized to measure the effects of vaccination on tau pathology
and inflammation.
Results: Humoral immune responses following immunization demonstrated robust antibody titers (up to 1:80,000
endpoint titers) to each tau species in both mice models. The number of IFN-γ producing T cells and their proliferation
were also increased in splenocytes from immunized mice, indicating an increased cellular immune response, and tau
levels and neuroinflammation were both reduced. We identified five immunogenic motifs within either the N-terminal
(9-15 and 21-27 amino acids), proline rich (168-174 and 220-228 amino acids), or the C-terminal regions (427-438 amino
acids) of the wild-type and P301L tau protein sequence.
Conclusions: Our study identifies five previously unknown immunogenic motifs of wild-type and mutated (P301L) tau
protein. Immunization with both proteins resulted in reduced tau pathology and neuroinflammation in a tau transgenic
model, supporting the efficacy of tau immunotherapy in tauopathy.
Keywords: Tau, Immunogenicity, Active immunization, Neuroinflammation, Peripheral responseIntroduction
Accumulation of the microtubule-associated protein tau in
the brain is linked to a number of neurodegenerative
diseases termed tauopathies. The most common of these is
Alzheimer’s disease (AD) [1]. Mutations in the MAPT gene
that encodes the tau protein are known to cause some of
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unless otherwise stated.dementia and progressive supranuclear palsy [2,3]. Human-
izing mice with transgenic insertion of these tau mutations
(i.e. P301L) has provided invaluable pre-clinical tools to
study tau pathogenesis. Studies using these mouse models
as well as tau knockout mice have shown that removing
tau could be beneficial for disease symptoms [4-7]. As a
result, a number of different strategies aimed at depleting
tau are being developed.
In recent years, the vaccine-based approach has shown
particular promise as a method of tau reduction. Develop-
ments in tau-targeted immunotherapeutic strategies have
suggested that both active and passive immunizationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the efficacy of these approaches is that, reminiscent of prion
propagation, tau can exit neurons, propagate to neighbor-
ing neurons, and corrupt their normal tau [12-14]. There-
fore, it has been speculated that this extracellular tau is
the primary target of immunological anti-tau approaches.
Passive immunization in particular has shown impressive
effects in pre-clinical models, and antibodies designed to
target distinct abnormal tau species, such as phospho-tau,
oligomeric tau, and even misfolded tau, have all proven
effective in mice [4,10,11,15-19].
While active immunization paradigms against self-
proteins will likely not be therapeutically relevant, they
have served as proof-of-principle for the vaccination ap-
proach in general. Indeed, active immunization of mice
with tau peptides produced tau antibodies that could
cross the blood-brain barrier, (BBB) reduce pathological
tau [1,20], and rescue functional impairments in tau
transgenic mice [9,10,21]. So far, however, these peptides
have all been generated based on pathological relevance
or predicted immunogenicity using algorithms; there has
not been an epitope map produced to identify the stron-
gest immunogens in the tau sequence. To fill this void,
we vaccinated both tau transgenic and non-transgenic
mice with human wild-type tau (Wt, 4R0N) protein or
human P301L tau (4R0N). Not only was tau pathology
found to be reduced after vaccination, but using the
anti-sera we created an epitope map via an innovative
peptide array approach that revealed the evolutionary
emergence of a novel tau immunogen found only in pri-
mates. In addition, we have determined that transgenic
and wild-type mice produce anti-sera with distinct
epitope profiles, depending on whether or not they were
vaccinated with wild-type tau or mutant P301L tau.
These findings suggest that specific tau regions are
highly immunogenic and may aid in the development of




The rTg4510 mouse breeding was performed by crossing
the parental human P301L tau mutation and tetracycline-
controlled transactivator (tTa) phenotypes as originally de-
scribed in [5]. Age-matched, non-transgenic littermates were
included in the study (in-house breeding). Animal proce-
dures were consistent with the recommendations of the
National Research Council’s “Guide for the Care and Use of
Laboratory Animals”, and were approved by the University
of South Florida animal care and use committee (IACUC).
Protein expression and purification
The human wild-type 4R0N Tau or human P301L tau
(4R0N) were expressed with N-terminal 6xHis-tags usingthe pET28 vector system (EMD Millipore, Darmstadt,
Germany). The plasmids were transformed into One Shot®
BL21 Star™ (DE3) E. coli cells from Invitrogen (Invitrogen,
Grand Island, NY, USA) and then grown in 1.0 L LB
media under kanamycin selection (50 μg/mL). Expression
was induced at optical density 0.7 with 1.0 mM isopropyl-
β-D-thiogalactopyranoside and growth continued for 3
hours at 37°C with 250 rpm shaking for aeration. Cells
were pelleted by centrifugation at 4,000 g for 15 minutes
at 4°C and resuspended in 35 mL lysis buffer (500 mM
NaCl, 10 mM Immidazole, 1.0 mM phenylmethylsulfonyl
fluoride, 10 mM Tris/HCl, pH 8.0). Resuspended pellets
were stored at −80°C.
Cells were thawed on ice and lysed by sonication. Lys-
ate was clarified by centrifugation at 50,000 g for 30 mi-
nutes at 4°C. The supernatant was then loaded on a pre-
charged Ni-NTA column (Qiagen, Valencia, CA, USA)
and washed with 50 mL wash buffer (500 mM NaCl, 10
mM Immidazole, 10 mM Tris/HCl, pH 8.0). The 6xHis-
tagged proteins were eluted in 20 mL elution buffer (500
mM NaCl, 250 mM Immidazole, 10 mM Tris/HCl, pH
8.0) and then concentrated to 2 mL using Millipore
Amicon Ultracel-10 centrifuge tubes (EMD Millipore).
The concentrated samples were then loaded on a HiLoad
16/600 Superdex 200 pg column (GE Healthcare, Pitts-
burgh, PA, USA) that was pre-equilibrated in size exclu-
sion buffer (500 mM NaCl, 0.5 mM EDTA, 0.1 mM DTT,
10 mM Tris/HCl, pH 8.0). Eluted fractions were pooled,
concentrated, and dialyzed into PBS (pH 7.4) overnight.
Samples were stored at −80°C.
Vaccination procedure and tissue collection
Male and female transgenic rTg4510 mice (5 months
old; n = 12) and their non-transgenic littermates (n = 12),
subdivided into six groups (n = 4 per group), were
immunized with either protein or PBS (control group,
Table 1). Mice were injected subcutaneously with a 100
μg tau antigen formulated with Quil-A adjuvant (20 μg
per mouse). All groups received three injections in alter-
nating weeks and were boosted an additional three times
(3 weeks apart) after a 10-week resting period with ap-
propriate antigen (Figure 1). Sera were collected at days
38, 68, and 147, and were used to measure anti-tau anti-
body responses. Mice were sacrificed with somnasol
(0.078 mg/ml pentobarbital, 0.01 mg/ml phenytoin so-
dium) at day 9 after the last immunization. Spleens were
removed and placed in 5 mL RPMI1640 (Invitrogen).
Blood was drawn intracardially and stored at 25°C for 1
hour, placed at 4°C overnight, and then centrifuged at
4,000 rpm for 10 minutes. Serum was collected and cen-
trifuged again at 7,000 rpm for 10 minutes. Brains were
collected following transcardial perfusion with 0.9% nor-
mal saline solution. Fixed mouse brains were cryopro-
tected in successive 24-hour incubations of 10%, 20%,
Table 1 Immunization paradigm and group assignment
Group Mice Immunogen Number of mice Route Adjuvant
1 Littermate Wt-Tau 4 Subcutaneous Quil A
2 rTg4510 Wt-Tau 4 Subcutaneous Quil A
3 Littermate P310L-Tau 4 Subcutaneous Quil A
4 rTg4510 P310L-Tau 4 Subcutaneous Quil A
5 Littermate PBS 4 Subcutaneous Quil A
6 rTg4510 PBS 4 Subcutaneous Quil A
rTg4510 mice (n = 12) and non-transgenic littermates (n = 12) were separated into 6 groups (n = 4 per group). Each mouse was subcutaneously injected with a mix
solution of 1.1 mg/ml of each protein formulated in 2.0 mg/ml Quil A adjuvant. Each groups respective immunogen, immunization route, and adjuvant used are
indicated. PBS, phosphate-buffered saline; Wt, wild-type.
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previously [22].
Tau peptide microarray
The tau peptide microarray was designed using 15-mer
peptides with four amino acid overhangs, spanning the
full sequence of PNS-tau (P10636-9) for a total of 187
tau peptides. Empty spots were used as negative con-
trols. The arrays were printed on single microscope
slides in triplicate (Jenrin Peptide Technologies, Berlin,
Germany). Binding was tested per manufacturer’s proto-
col using plasma, diluted 1:100 in binding buffer (PBS/
0.1% Tween/2% bovine serum albumin) from animals
treated with either Wt-tau or P301L tau protein. Binding
was detected using a 1:500 titer of HiLyte Fluor 555-labeled
goat anti-mouse IgG antibody (Anaspec, Fremont, CA,
USA) in binding buffer. Arrays were scanned at a fluores-
cence emission of 532 nm using a GenePix 4100A Micro-
array Scanner (Molecular Devices, Sunnyvale, CA, USA)
and raw intensities adjusted by background subtractionFigure 1 Structure and purification of recombinant tau proteins follo
the sequence and commassie stain of recombinant full length tau protein
(B) Non-transgenic and rTg4510 mice were immunized three times in alter
three times every 3 weeks. After the vaccination period, tissue and blood
neuropathological changes. Ab, antibody; MW, molecular weight.(morphological closed followed by opening) using the scan-
ner software (GenePix Pro 7, Molecular Devices, Sunnyvale,
CA, USA). Binding was defined as peptides with fluores-
cence intensity greater than 3 standard errors above the
mean of the slide intensities. In order to identify false posi-
tives, a microarray was incubated with the antibody alone.
No signal was observed, so all peptides were included in
the analysis.
Detection of anti-tau antibody responses
Mice were bled from the submandibular region at days 0
(pre-bleed), 38, 68, and 147 of the immunization sched-
ule. The titers of anti-tau antibodies were determined by
ELISA as described previously [23], with minor modifi-
cations. Briefly, 96-well plates (Immunol 2HB; Fisher
Scientific, Pittsburgh, PA, USA) were coated with 100
μL of 10 μg/ml Wt-tau and P301L-tau (pH 9.7, over-
night at 40°C). Wells were washed and blocked with 3%
non-fat milk in 1xTris-Tween buffered saline overnight,
and then 100 μL of pooled sera from immunized micewed by the immunization paradigm. (A) Schematic presentation of
(wild-type (Wt)-tau, 4R0N) or tau mutated at P301L (P301L-tau, 4R0N).
nating weeks, followed by a 10-week resting period, then boosted
specimens were analyzed for cellular immune responses and
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bation and washing, HRP-conjugated goat anti-mouse IgG
(1:2,500, Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) was used as a secondary antibody. Plates
were incubated and washed, and the reaction was devel-
oped by adding 3,3′,5,5′ tetramethylbenzidine (Pierce,
Rockford, IL, USA) substrate solution and stopped with 2
M H2SO4. The optical density was read at 450 nm (Biotek,
Synergy HT, Winooski, VT, USA). Endpoint titers of anti-
bodies were calculated as the reciprocal of the highest sera
dilution that gave a reading twice above the cutoff. The
cutoff was determined as the titer of pre-immune sera at
the same dilution. The above procedure was repeated a
total of three times, with inter-assay variations of only 6 to
10%. Average data of three ELISAs are presented. For
determination of endpoint titers, sera were serially diluted
up to 1:102,000 from an initial dilution of 1:3,000. HRP-
conjugated anti-IgG1, IgG2ab, IgG2b and IgM specific
antibodies (1:2000; Bethyl Laboratories, Inc., Montgomery,
TX, USA) were used to characterize the isotype profiles of
anti-tau antibodies in individual serum (day 38) at dilution
1:1,000 (plates were coated with Wt-tau protein). The
optical density at 450 nm values for pre-bleed (day 0)
samples were subtracted from the day 38 samples.
Detection of cellular immune responses
T-cell proliferation analysis was performed in splenocyte
cultures from individual animals using [3H]-thymidine in-
corporation assays, as previously described in [23]. Spleno-
cytes were re-stimulated in vitro with Wt-tau, P301L-tau
or irrelevant proteins. Cells were first incubated for 72 hours,
then 1 μCi of [3H]-thymidine (Amersham Biosciences,
Piscataway, NJ, USA) was added to each well for 16 to
18 hours. Cells were harvested using the Tomtec Mach III
harvester (TOMTEC LifeSciences, Hamden, CT, USA), and
[3H] thymidine uptake (cpm) was counted on a Microbeta
1450 Trilux scintillation counter (Wallac, Pelkin-Elmer,
Waltham MA, USA). The stimulation index was calculated
as previously described in [23]. The same splenocytes were
also used to assess T-cell activation through IFNγ ELISPOT
assays (BD Pharmingen, San Jose, CA, USA), as previously
described [24]. Splenocytes from individual mice were re-
stimulated with Wt-tau, P301L-tau, or irrelevant proteins.
Spots were counted using a CTL-Immunospot S5 Macro
Analyzer (Cellular Technology Ltd., Shaker Heights, OH,
USA). The difference in the number of spot forming col-
onies per 106 splenocytes that were re-stimulated with
vaccine-related proteins and those found in 106 splenocytes
re-stimulated with irrelevant proteins was calculated. All
proteins were used at 10 μg/ml.
Immunohistochemical analysis
Immunohistochemistry was performed on free-floating sec-
tions as recently described in [25]. A series of six sectionsper animal were incubated with each primary antibody
overnight at room temperature. The following primary
antibodies were used for immunohistochemistry: anti-total
tau (H150, Santa Cruz Biotechnologies, Dallas, TX, USA);
anti-phospho-tau at Serine 396 (pS396), anti-phospho-tau
at 199/202 (pS199/202, Anaspec, Fremont, CA, USA); anti-
phospho-tau at Serine 202 and Threonine 205 (biotinylated
AT8, ThermoScientific, Waltham, MA, USA); anti-Paired
Helical Filament-1 tau (PHF1/pS396-404, kind gift from Dr
Peter Davies, Albert Einstein College of Medicine, Yeshiva
University); anti-Cluster of Differentiation 45 (CD45, Ther-
moScientific); anti-Cluster of Differentiation 11b (CD11b,
AbD Serotec, Raleigh, NC, USA); anti-glial fibrillary acidic
protein (GFAP; DAKO, Carpinteria, CA, USA); anti-major
histocompatibility complex II (BD Biosciences, San Jose,
CA, USA). HRP- and biotin-conjugated secondary anti-
bodies were obtained from VectorLabs (Burlingame, CA,
USA), while conjugated AlexaFluor594/488 secondary anti-
bodies were purchased from Invitrogen. Color development
was performed using 0.05% 3,3′-diaminobenzidine (Sigma,
St Louis, MO, USA) enhanced with 0.5% nickelous ammo-
nium sulfate (J.T. Baker Chemical Company, Phillipsburg,
NJ, USA). Gallyas histology was performed as described in
[26] using sections that were pre-mounted on slides and
then air dried for a minimum of 24 hours.
Stained sections were imaged using a Zeiss Mirax150
digital scanning microscope (Carl Zeiss MicroImaging,
GmbH Clincial, 07740 Jena, Germany). For quantifica-
tion, regions of anterior cortex, hippocampus and the
entorhinal cortex were analyzed by using hue, saturation
and intensity for each image field. Thresholds for object
segmentation were established with images of high and
low levels of staining to identify positive staining over all
intensity levels within the study. These limits were held
constant for the analysis of every section in each study
according to Gordon and colleagues [27].
Statistical analysis
Statistical analyses were performed using Student’s t-test
or one-way analysis of variance followed by Fischer’s
LSD post hoc means comparison test using Stat View
software version 5.0 (SAS Institute Inc., Cary NC, US).
Graphs were generated using GraphPad Prism 5.0 (La
Jolla, CA, USA). The average% positive area value mea-
sured by immunohistochemistry was normalized to the
PBS controls.
Results
Active immunization induces robust anti-tau antibody
response
The beneficial effects of tau immunotherapy have been
previously demonstrated by several research laboratories
[8,10,11,19,21,28]. To date, there have been no investiga-
tions of immunogenicity of various forms of tau protein
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following vaccination. Therefore, 5-month-old trans-
genic rTg4510 mice with existing pathology (n = 12) and
non-transgenic littermates (n = 12) were immunized as
shown in Figure 1 and Table 1. The rTg4510 mouse
model was chosen because it is currently the state-of-
the-art mouse model for tauopathy. It is one of the only
models to produce the pathological conformations ne-
cessary to induce Gallyas silver positive staining, which
is a common benchmark for identifying tangle pathology
in humans. In addition, these mice develop pathology in
the forebrain, which begets neuronal loss and glial acti-
vation [5,26,29]. Pooled sera from mice bled at days 38,
68, and 147 were analyzed via ELISA. On day 38, both
transgenic and non-transgenic mice showed robust anti-
body titers specific to each tau form (Wt or P301L).
These antibodies remained present during the rest
period (day 68), suggesting a persistent antigen-specific
immune response. The antibody titers increased following
booster injections on day 147. During the experimental
course, no significant difference in titer quantities were
measured between Wt-tau or P301L-tau in vaccinated
rTg4510 (Figure 2A,B) and littermate mice (Figure 2D,E).
After immunizations of mice with both proteins, levels of
anti-tau titers are higher in littermates compared to P301L
mice, which could be related with the mechanism of self-
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Figure 2 Immunizations with Wt-tau and P301L-tau proteins formulat
rTg4510 and littermate mice. Mean endpoint antibody titers specific for
sera of mice (n = 4 per group) at days 38, 68, and 147. Endpoint titers of antibo
of 1:3,000) with two-fold signal above the cutoff. The cutoff was determined as
three times and average ± SD of three ELISAs is presented (student’s t-test was
and littermates at day 38 (1:1,000) were analyzed and IgG anti-tau antibody of
average ± SD (n = 4).foreign and self-molecules equally well; however, CD4+ T
helper cell receptors recognize mostly foreign, but not self-
peptides presented by self-major histocompatibility com-
plex class II molecules. Therefore, it is not surprising that
the levels of anti-tau titers are low in rTg4510 mice since
the tau protein is a self-antigen for these animals. The gen-
eration of a potent antibody response to tau vaccination
requires the breaking of natural tolerance to self-antigens.
Formulation of antigen in strong adjuvant helps to breake
the tolerance although the response could be still lower
compared with foreign antigen (in this case human tau in
non-transgenic mice). As expected, the control PBS injec-
tion did not elicit antibody production in these mice
(data not shown).
Analyzing the isotype of antibody produced, we showed
that injection of either the wild-type or P301L recombin-
ant tau induced in all immunized mice an almost equal
IgG1, IgG2ab, and IgG2b isotype response, but a much
lower IgM response (Figure 2C,D). Overall, the average
abundance of the generated isoforms was independent of
genotype and antigen and ranked as follows: IgG1 >
IgG2b > IgG2ab > IgM.
Immunization with tau proteins induces a strong cellular
immune response
To discern the levels of T cell proliferation following
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ed in Quil-A induced robust titers of anti-tau antibody in
wild-type (Wt)-tau (A,D) and P301L-tau (B,E) were evaluated in pooled
dies represents the highest sera dilution (1:108,000 from and initial dilution
the titer of pre-immune sera at the same dilution. ELISAs were repeated
performed, **P< 0.01). (C,F) Individual sera of immunized rTg4510 mice
IgG1, IgG2ab, and IgG2b isotypes were detected. Error bars indicate the
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incorporated into cells as they proliferated. Splenocytes from
experimental and control groups of rTg4510 mice vacci-
nated with the Wt- or P301L-tau induced strong T-cell
proliferation, though the control PBS did not (Figure 3A).
These strong cellular immune responses in all vaccinated
mice were confirmed by measuring the number of IFN-γ
producing T cells (Figure 3B). PBS-injected mice exhibited
only background levels of spot-formulating cells after
in vitro re-stimulation with both proteins (Figure 3B). This
data demonstrates that immunization of rTg4510 mice
with each tau protein elicits a robust and specific anti-tau
antibody generation, followed by a strong cellular immune
response.
Identification of tau immunogenicity
The above findings suggest that regions of tau sequence
can elicit both humoral and cellular activation. As tau
immunotherapies continue to be a promising approach
in neurodegenerative disease, it is attractive to pursue
studies where tau epitopes are targeted based on their
sequence immunogenicity profile. To identify immuno-
genic tau peptides responsive to the vaccination para-
digm, we performed tau epitope mapping by utilizing a
novel peptide microarray composed of 15-mer peptides
covering the longest isoform of tau expressed in the
peripheral nervous system [30]. These tau peptides were
assembled with four amino acid overlaps, and each
presented in triplicate on glass slides. Binding of sera
from animals vaccinated with Wt-tau or P301L-tau to
these peptide arrays was measured using fluorescent
anti-mouse IgG antibody. Negative controls consisted of
fluorescent anti-mouse IgG antibody alone. As expected,
the negative controls bound nonspecifically to very few
peptides, which were excluded from subsequent ana-
lyses. In contrast, sera from Wt-tau and P301L-tau im-
munized rTg4510 and non-transgenic animals bound to
a number of tau-derived peptides (Figure 4A, AdditionalFigure 3 Cellular immune responses specific to different tau proteins
wild-type (Wt)- or P301L-tau proteins. (A) Proliferation of T cells is detec
obtained from experimental and control animals and expressed as stimulat
SFC) is detected by ELISPOT assay in splenocyte cultures obtained from imfile 1: Table S1). Analysis of the fluorescence intensity
measured in this assay identified ten epitopes with high
immunogenicity (Additional file 2: Table S2). Further
analyses ranked the sequences with the highest flores-
cence intensity, as outlined in Figure 4B. These motifs
lay within the N-terminal region (9-15 and 21-27 amino
acids), proline rich region, microtubule binding region
(168-174 and 220-228 amino acids) and the C-terminal
region (427-438 amino acids) (Figure 4). The 2 N-insert
tau region displayed low binding activity toward any of
the tau forms tested in the array (Figure 4A). The pep-
tide microarray findings suggest that these sequences
can elicit antigen-induced peripheral immune activation.
Efficacy of anti-tau immunization in neuroinflammation
We have previously shown that rTg4510 mice display in-
duced levels of inflammation with age [26]. To assess the
neuroinflammatory response following immunization, and
to see whether a tau-induced immune response in the per-
iphery can translate into changes in the central nervous
system neuroinflammatory mileu, we investigated the state
of microglial (anti-CD45, anti-CD11b) and astrocytic acti-
vation (anti-GFAP) by a immunohistochemical approach,
using markers associated with microglia and astrocyte
activation [31,32]. Quantification of percent positive area
showed significant CD45 reduction in the anterior cortex
(Wt- and P301L, P < 0.01 versus P < 0.05, respectively),
hippocampus (P < 0.005 and P < 0.05, respectively), and
entorhinal cortex (P < 0.0001 and P < 0.05, respectively).
Non-transgenic mice displayed quiescence microglia
morphology (insets in Figure 5A) and low levels of CD45
immunoreactivity (Figure 5B). Furthermore, vaccinated
rTg4510 mice displayed reduced levels of CD11b-positive
microglia in the brain (Figure 6A, red fluorescent), reach-
ing levels comparable to those measured in immunized
non-transgenic mice (Figure 6B). In agreement with previ-
ous data, rTg4510 mice have augmented microglia burden
[26] as shown by the increased CD11b levels in PBS-were detected in rTg4510 mice following immunizations with
ted by [3H]-thymidine incorporation assay in splenocyte cultures
ion index. (B) Number of IFN-γ producing cells (spot formatting cells,
munized rTg4510 mice. Bars represent average ± SD (n = 4).
Figure 4 Immunogenicity of tau protein detected by spot array. (A) The profile of the epitope mapping experiment where the fluorescence
intensities at a wavelength of 532 nm, after background subtraction, for each animal group tested in duplicate is shown. The domain organization of
human tau in the central nervous system (441 residues, htau40) containing the I1-I2 inserts on the N-terminal and the R1-R4 repeats is shown. The domain
boundaries are labeled by the residue numbers. Five peaks displayed the highest fluorescence intensity (peak 1-5). (B) Amino acid sequence of 4R2N
expressed in the central nervous system. Blue colored amino acids represent the five peptide sequences with the highest immunogenicity identified in the
spot array. Each highlighted peptide sequence corresponds to the peak 1-5 in (A). Average fluorescence intensity ± SEM is shown for each sequence. a.u.,
Area under; Tg, transgenic; WT, wild-type.
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green fluorescent) showed significant GFAP signal reduc-
tion in P301L-tau immunized mice (P < 0.0066), while only
slight reductions were observed in the Wt-tau immunized
mice compared to the PBS-injected animals. Non-
transgenic mice showed low levels of astrocyte activation
in the brain (Figure 6C). Overall, vaccination of rTg4510
mice resulted in reduced neuroinflammatory milieu with
no effect present in immunized non-transgenic littermates.
Immunization against Wt- or P301L-tau protein signifi-
cantly reduces pathology in rTg4510 mice
Finally, we investigated the impact of immunization on
tau pathology in transgenic mice by performing immuno-
histochemistry (Figure 7 and Table 2). Staining of brain
tissue showed significant reductions in total tau (H150,
Figure 7C) following vaccination with Wt-tau but not
P301L-tau injected rTg4510 mice (Table 2; P = 0.0179 and
P = 0.6452, respectively). As indicated in Figure 7A,D, we
observed significant reduction in pS202-Thr205 tau levels(AT8) in transgenic mice vaccinated with both Wt-tau
and P301L-tau (Table 2; P = 0.0295 and P = 0.0377, re-
spectively). The results from tissue analysis from several
phospho-tau antibodies and aggregated tau (Gallyas stain)
are summarized in Table 2. Consistent with previous stud-
ies [33], the immunohistochemical analyses suggest a
beneficial effect of tau vaccination regarding reduction in
cerebral tauopathy and inflammation in the rTg4510
mouse model.
Discussion
Immunotherapeutic approaches to treat tauopathies are
being intensively pursued by both academia and indus-
try. While active immunization strategies will likely not
be a viable therapeutic approach due to concerns about
auto-immunity and micro-hemorrhage, it could be useful
for understanding the interface between the immune re-
sponse and tau pathogenesis. Using active immunization
against the 4R0N wild-type or P301L tau, we determined
the most immunogenic epitopes in the central nervous
Figure 5 Reduced activated microglia burden following
immunization with wild-type (WT)- or P301L-tau proteins. (A)
Representative micrographs of brain regions (anterior cortex (ACX),
hippocampus (HPC), and entorhinal cortex (ECX)) immunostained for
CD45 microglia marker. (B) Percent positive area analysis of the brain
regions demonstrated significant reductions in CD45 microglia burden
in both Wt-tau and P301L-tau immunized rTg4510 animals. Immunized
non-transgenic animals displayed low levels of activated microglia,
hence pooled values were graphed. One way analysis of variance,
*P < 0.05, **P < 0.01, ***P < 0.001. Scale bar is 200 μm, inset 20 μm.
NTG, non-transgenic; PBS, phosphate-buffered saline.
Figure 6 Reduced inflammation following vaccination with
wild-type (Wt)- or P301L-tau proteins. (A) Representative
micrographs of hippocampal region positive stain for glial fibrillary
acidic protein (GFAP; green) and CD11b (red) in immunized rTg4510
and non-transgenic (NTG) littermates. (B,C). Quantification of percent
positive area of hippocampus demonstrated significant reduction in the
levels of GFAP following P301L-tau but not Wt-tau immunization. No
significant reduction in CD11b immunoreactivity was observed following
rTg4510 mice immunization compare to phosphate-buffered saline
(PBS)-injected littermates. Immunized non-transgenic animals displayed
low levels of GFAP and CD11b immunoreactivity (pooled values). Values
are normalized to the PBS control group and student’s t-test was
performed, **P< 0.01. Scale bar is 200 μm for regions, 20 μm for insets.
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http://www.jneuroinflammation.com/content/11/1/152system tau isoform. One of these epitopes (amino acids
21-27 GDRKDQG), a sequence that introduces a caspase
cleavage DXXD motif and is linked to tau pathogenesis, is
exclusively found in tau from primates, suggesting that
the evolutionary insertion of this fragment could be an
important reason for the emergence of tau pathogenesis
in humans. In addition, we show that while non-
transgenic and tau transgenic mice do produce some simi-
lar epitopes to wild-type and mutant human tau, they also
produce anti-sera to unique epitopes. Subcutaneous injec-
tions of Wt-tau and P301L-tau proteins in the rTg4510
mouse model and non-transgenic littermates resulted in
equal and robust antibody titers and cellular immune
response specific to both antigens, and active vaccination
with either tau protein similarly reduced tau pathology
and neuro-inflammation in tau transgenic mice, though
not to the extent expected based on previous work. One
possibility may be that peripheral immune cells are the
major contributor to the beneficial effects of vaccination
more than resident microglia, as previously described
[34-36], but, perhaps by improving antigen design basedon antigen profiling data, the efficacy of vaccination strat-
egies can be advanced. Using a peptide microarray assay,
we identified several tau regions with similar immunogen-
icity in non-transgenic and rTg4510 mice immunized with
either Wt or mutant P301L tau. These common active
epitopes were found throughout the protein: two were
located in the N-terminal (9-15 and 21-27 amino acids;
EVMEDHAG, GDRKDQ), one in the proline rich region
(168-174 and 220-228 amino acids; ATRIPAK, TREPKKV)
and one at the extreme C-terminal region (427-438 amino
acids TLADEVSASLAK). Each of these immunogenic re-
gions was of particular interest because of their biological
significance.
The 9-15 amino acids, 21-27 amino acids, and 427-
438 amino acids sequences are within regions that are
cleaved by caspases [37,38]. In vitro, N-terminal cleavage
of tau has been suggested to occur at the aspartic acid
position 13 (VMED*-), but other potential cleavage sites
are also present (for example, the DXXD motif within
Figure 7 Vaccination with wild-type (WT)- or P301L-tau proteins reduced tau pathology. (A) Micrographs of brain regions (anterior cortex
(ACX), hippocampus (HPC), and entorhinal cortex (ECX)) immunostained for total-tau (H150) and (B) AT8 (pS202-Thr205). (C) Analysis of percent
positive area in each region demonstrated significant reduction of total tau in the animals immunized with Wt-tau, while (D) reduction in AT8
(pS202-Thr205) tau levels was observed in both groups as compared to phosphate-buffered saline (PBS)-injected animals. Values are normalized
to PBS controls and student t-test was performed, *P < 0.05. Scale bar is 200 μm for regions, 20 μm for insets.
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terminal truncation decreases tau polymerization in vitro,
studies have suggested that the Alz50-Tau66 conform-
ation, which requires the N-terminus, can stabilize exist-
ing filaments and contribute to tangle maturation in AD
[37]. The in vitro D421 truncation of tau (DMVD*-) can
nucleate tangle formation [40-42]. Moreover, tau that is
released from neurons has been found to be caspase
cleaved. The accumulation of tau cleaved at amino acid
421 into tangles has been demonstrated in the brains of
several animal models [43,44] and in AD patients [45].
Combined with our new data, it suggests that tau outside
of neurons and accumulating into tangles may lack a key
immunogenic epitope that could assist in its clearance.
However, when tau is phosphorylated at S422, its caspase
cleavage is blocked and this phospho-tau species is also
found in tangle pathology. In fact, a previous study
showed that active immunization targeting pS422 in tautransgenic mice led to an immune response and reduction
of tau pathology followed by significant cognitive im-
provement [21]. These findings suggest that multiple
factors can contribute to tau pathology, and the interface
between the biology and immunological response to these
distinct tau species could be essential to designing im-
proved treatments targeting tau.
The tau immunogens within the proline-rich region at
168-174 amino acids and 220-226 amino acids also are
near a number of consensus sites for known tau kinases:
microtubule affinity regulating kinase (MARK), mitogen
activated protein kinase (MAPK), cAMP-dependent pro-
tein kinase and glycogen synthase kinase 3 (GSK3). Sys-
temic studies suggests that phosphorylation of tau by
proline-directed kinases (MAPK and GSK3) in the re-
gions adjacent to the repeat domain (R1-R4) had a weak
negative effect on tau-microtubule interactions as well
as tau aggregation into paired helical filaments (PHF)
Table 2 Immunohistochemical changes measured in
immunized mice





Wt-tau 0.68 ± 0.03* 0.0179*
P301L tau 0.87 ± 0.17 0.6452
AT8 (pS202-Thr205)
Wt-tau 0.58 ± 0.05* 0.0295*
P301L tau 0.55 ± 0.03* 0.0377*
pS199/202
Wt-tau 0.59 ± 0.04 0.0721
P301L tau 1.29 ± 0.19 0.3600
pS396
Wt-tau 0.96 ± 0.06 0.8089
P301L tau 0.99 ± 0.04 0.9700
Gallyas
Wt-tau 1.27 ± 0.06 0.4596
P301L tau 0.81 ± 0.06 0.5839
CD45
Wt-tau 0.4 ± 0.03 0.0001*
P301L tau 0.51 ± 0.03 0.0001*
CD11b
Wt-tau 0.12 ± 0.07 0.1202
P301L tau 0.04 ± 0.02 0.0550
GFAP (HPC)
Wt-tau 0.85 ± 0.1 0.2977
P301L tau 0.7 ± 0.05 0.0066*
The ratio of percent positive area values for each immunized group to the
phosphate-buffered saline (PBS)-injected mice is presented for total tau, p-tau
and inflammatory markers (average ± SEM). Values in bold and asterisk
indicate markers that are significantly reduced by immunization. Statistical
analyses were performed by student’s t-test, *P < 0.05. GFAP, glial fibrillary
acidic protein; HPC, hippocampus; Wt, wild-type.
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with a mixture of phopho-Tau195-203, 207-220 and
224-238 peptides demonstrated a reduction in levels of
phospho-tau and neurofibrillary tangle burden [28], indi-
cating beneficial effects of targeting this region. Interest-
ingly, none of the five most potent immunogens were
located within the microtubule binding domain of tau,
despite this being the region where most disease-causing
mutations lie and the region that is the most active with
regard to function and aggregation. However, some of
the less potent epitopes did lie within the microtubule
binding domain. In particular, we found that only vacci-
nated tau transgenic rTg4510 mice produced antisera
with activity against epitopes containing consensus sites
for MARK2 (amino acids 292-302 and 356-366). These
sites are known to be very important for tau function
and pathogenicity. When phosphorylated at these sites, tauattachment to microtubules was inhibited and had a greater
propensity to aggregate [46,48]. Tau phosphorylated at
these sites is also found in tau tangles [49]. It is possible
that when these sites are phosphorylated, their immuno-
genicity is changed, contributing to tau accumulation. It
also suggests that over-expression of mutant tau can expose
distinct epitopes that could be exploited to treat specific
tauopathy subtypes.
Immunotherapy targeting tau is under intensive investi-
gation. Understanding the interface between tau and the
immune system could prove invaluable for improving im-
munotherapy approaches. Passive immunization strategies
have shown great promise in pre-clinical models. Studies
have shown that FITC-labeled antibodies can not only
cross the blood-brain barrier [21] but also enter neurons
and bind intracellular tau both in vivo and ex vivo [10,50].
In fact, these internalized antibodies co-localize with
pathological tau markers inside the neurons containing
tau pathology [20], and can prompt the clearance of intra-
cellular tau aggregates through the endosomal/lysosomal
system [51,52]. Recent advances in tau biology have shown
that tau can exit neurons and propagate throughout the
brain [53], suggesting that tau immunotherapy may work
on both internal and external tau epitopes [12,13,54]. By
defining the most potent immunogens within the tau pro-
tein and showing that the genetic environment of the host
can lead to distinct immunogen profiles, new tools may be
designed to better understand these mechanisms as well as
improve the potential efficacy of passive immunization
strategies that are rapidly progressing in the clinic.
Conclusions
The present study provides the immunogenic profile to two
different tau species in both wild-type and tau over-
expressing mice, a tool that could be useful for the tau im-
munotherapy field moving forward. It also provides further
support to the growing evidence that tau immunotherapy
can effectively reduce tau pathology and neuroinflammation.
Interestingly, one of the most immunogenic epitopes (amino
acids 21-27) is conserved only in primates and humans, and
this region has previously been linked to tau pathogenesis.
Thus, perhaps this region contributes to disease pathogen-
esis through this previously unknown mechanism.Additional files
Additional file 1: Table S1. Complete list of identified tau
immunogenic epitopes. The peptide sequences in tau proteins were
detected as immunogenic motifs based on their florescence intensity in
the array (threshold cut off ≥10,000 relative intensity). The residues
identified by two independent experiments are labeled as x2.
Additional file 2: Table S2. The peptide sequence and residue
positions of immunogenic tau. Peptide sequence (red) corresponding to
top ten immunogenic peptide motifs displaying the highest fluorescence
intensity in the spot array.
Selenica et al. Journal of Neuroinflammation 2014, 11:152 Page 11 of 12
http://www.jneuroinflammation.com/content/11/1/152Abbreviations
AD: Alzheimer’s disease; ELISA: enzyme-linked immunosorbent assay;
GFAP: glial fibrillary acidic protein; GSK3: glycogen synthase kinase 3;
HRP: horse radish peroxidase; Ig: immunoglobulin; IFN: interferon;
MAPK: mitogen activated protein kinase; MARK: microtubule affinity
regulating kinase; PBS: phosphate-buffered saline; Wt: wild-type.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CAD contributed in the connectional design of the study. MLBS and CAD
designed and coordinated the experimental activities. HD performed B and T
cell analysis. SBH, JL, LJB and BZ performed animal injections and collection
of sera and spleens. BAN produced and purified all tau proteins used in the
study. AG performed peptide microarray. AG and MLBS analyzed the data.
SBH, DCL and JL performed immunohistochemical procedures and data
analysis. SBH and MLBS wrote the manuscript. CAD made valuable
contributions in revising the manuscript. DM, DCL and MNG made
intellectual contributions to the data interpretation. All authors have read
and approved the final version of the manuscript.
Acknowledgments
This work was supported by NINDS R01 NS073899 and NIRG 13-281227
(Alzheimer’s Association). We would like to thank Prof. Michael G Agadjanyan,
PhD, DSc, at the Department of Immunology, Institute for Molecular Medicine,
Huntington Beach, CA, USA, for his valuable consulting on the interpretation of
the immune responses measured in the sera and splenocytes.
Author details
1Department of Pharmaceutical Sciences, College of Pharmacy, University of
South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA. 2USF
Health, Byrd Alzheimer Institute, 4001 E. Fowler Avenue, MDC 36, Tampa, FL
33613, USA. 3Department of Molecular Immunology, Institute for Molecular
Medicine, 16371 Gothard Street, H, Huntington Beach, CA 92647, USA.
4Institute for Memory Impairments and Neurological Disorders, University of
California, 2642 Biological Sciences III, Irvine, CA 92697, USA. 5Department of
Molecular Pharmacology and Physiology, Morsani College of Medicine,
University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL 33612,
USA. 6Department of Molecular Medicine, Morsani College of Medicine,
University of South Florida, 4001 E. Fowler Avenue, MDC 36, Tampa, FL
33613, USA. 7Life Sciences Institute, University of Michigan, Ann Arbor, MI,
USA.
Received: 13 June 2014 Accepted: 14 August 2014
References
1. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM: Tau-targeted immunization
impedes progression of neurofibrillary histopathology in aged P301L tau
transgenic mice. PLoS One 2011, 6:e26860.
2. Armstrong RA, Lantos PL, Cairns NJ: Progressive supranuclear palsy (PSP):
a quantitative study of the pathological changes in cortical and
subcortical regions of eight cases. J Neural Transm 2007, 114:1569–1577.
3. Riedl L, Mackenzie IR, Forstl H, Kurz A, Diehl-Schmid J: Frontotemporal
lobar degeneration: current perspectives. Neuropsychiatr Dis Treat 2014,
10:297–310.
4. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst
M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Dickson DW, Davies P,
Hutton M: Neurofibrillary tangles, amyotrophy and progressive motor
disturbance in mice expressing mutant (P301L) tau protein.
Nat Genet 2000, 25:402–405.
5. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes
A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C,
Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH: Tau suppression in
a neurodegenerative mouse model improves memory function.
Science 2005, 309:476–481.
6. Denk F, Wade-Martins R: Knock-out and transgenic mouse models of
tauopathies. Neurobiol Aging 2009, 30:1–13.
7. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K,
Davies P: Hyperphosphorylation and aggregation of tau in miceexpressing normal human tau isoforms. J Neurochem 2003,
86:582–590.
8. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM: Passive
immunization targeting pathological phospho-tau protein in a mouse
model reduces functional decline and clears tau aggregates from the
brain. J Neurochem 2011, 118:658–667.
9. Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting
pathological tau prevents cognitive decline in a new tangle mouse
model. J Neurosci 2010, 30:16559–16566.
10. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy
targeting pathological tau conformers in a tangle mouse model reduces
brain pathology with associated functional improvements. J Neurosci
2007, 27:9115–9129.
11. D’Abramo C, Acker CM, Jimenez HT, Davies P: Tau passive immunotherapy
in mutant P301L mice: antibody affinity versus specificity.
PLoS One 2013, 8:e62402.
12. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K:
Trans-synaptic spread of tau pathology in vivo. PLoS One 2012, 7:e31302.
13. Frost B, Jacks RL, Diamond MI: Propagation of tau misfolding from the
outside to the inside of a cell. J Biol Chem 2009, 284:12845–12852.
14. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH,
Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL,
Hyman BT: Propagation of tau pathology in a model of early Alzheimer’s
disease. Neuron 2012, 73:685–697.
15. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA,
Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R:
Passive immunization with Tau oligomer monoclonal antibody reverses
tauopathy phenotypes without affecting hyperphosphorylated
neurofibrillary tangles. J Neurosci 2014, 34:4260–4272.
16. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves
CA, Kayed R: Specific targeting of Tau oligomers in htau mice prevents
cognitive impairment and Tau toxicity following injection with brain-derived
Tau oligomeric seeds. J Alzheimers Dis 2014, 40:S97–S111.
17. Kayed R: Anti-tau oligomers passive vaccination for the treatment of
Alzheimer disease. Hum Vaccin 2010, 6:931–935.
18. Boutajangout A, Sigurdsson EM, Krishnamurthy PK: Tau as a therapeutic
target for Alzheimer’s disease. Curr Alzheimer Res 2011, 8:666–677.
19. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J,
Davies P, O’Neill MJ, Hutton ML, Citron M: Passive immunization with
anti-Tau antibodies in two transgenic models: reduction of Tau pathology
and delay of disease progression. J Biol Chem 2011, 286:34457–34467.
20. Gu J, Congdon EE, Sigurdsson EM: Two novel Tau antibodies targeting the
396/404 region are primarily taken up by neurons and reduce Tau
protein pathology. J Biol Chem 2013, 288:33081–33095.
21. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME,
Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L: Targeting
phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse
model: a suitable therapeutic approach. Curr Alzheimer Res 2012,
9:397–405.
22. Selenica ML, Brownlow M, Jimenez JP, Lee DC, Pena G, Dickey CA, Gordon
MN, Morgan D: Amyloid oligomers exacerbate tau pathology in a mouse
model of tauopathy. Neurodegener Dis 2013, 11:165–181.
23. Davtyan H, Mkrtichyan M, Movsesyan N, Petrushina I, Mamikonyan G, Cribbs
DH, Agadjanyan MG, Ghochikyan A: DNA prime-protein boost increased
the titer, avidity and persistence of anti-Abeta antibodies in wild-type
mice. Gene Ther 2010, 17:261–271.
24. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N,
Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG: Alzheimer’s
disease peptide epitope vaccine reduces insoluble but not soluble/
oligomeric Abeta species in amyloid precursor protein transgenic mice.
J Neurosci 2007, 27:12721–12731.
25. Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, Reid P, Mouton PR,
Morgan D, Gordon MN: Diverse activation of microglia by chemokine (C-C
motif) ligand 2 overexpression in brain. J Neuroinflammation 2013, 10:86.
26. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN,
Dickey CA, Morgan D: LPS-induced inflammation exacerbates phospho-
tau pathology in rTg4510 mice. J Neuroinflammation 2010, 7:56.
27. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor
K, Melachrino J, O’Callaghan JP, Morgan D: Time course of the development
of Alzheimer-like pathology in the doubly transgenic PS1 + APP mouse.
Exp Neurol 2002, 173:183–195.
Selenica et al. Journal of Neuroinflammation 2014, 11:152 Page 12 of 12
http://www.jneuroinflammation.com/content/11/1/15228. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann
H: Efficacy and safety of immunization with phosphorylated tau against
neurofibrillary tangles in mice. Exp Neurol 2010, 224:472–485.
29. Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L, Lee
D, Dickson D, de Silva R, Binder LI, Morgan D, Lewis J: Aging analysis
reveals slowed tau turnover and enhanced stress response in a mouse
model of tauopathy. Am J Pathol 2009, 174:228–238.
30. Thompson AD, Scaglione KM, Prensner J, Gillies AT, Chinnaiyan A, Paulson
HL, Jinwal UK, Dickey CA, Gestwicki JE: Analysis of the tau-associated
proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau
degradation. ACS Chem Biol 2012, 7:1677–1686.
31. Lee DC, Ruiz CR, Lebson L, Selenica ML, Rizer J, Hunt JB Jr, Rojiani R, Reid P,
Kammath S, Nash K, Dickey CA, Gordon MN, Morgan D: Aging enhances
classical activation but mitigates alternative activation in the central
nervous system. Neurobiol Aging 2013, 34:1610–1620.
32. Colton C, Wilcock DM: Assessing activation states in microglia.
CNS Neurol Disord Drug Targets 2010, 9:174–191.
33. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF,
Diamond MI, Holtzman DM: Anti-tau antibodies that block tau aggregate
seeding in vitro markedly decrease pathology and improve cognition
in vivo. Neuron 2013, 80:402–414.
34. Prinz M, Mildner A: Microglia in the CNS: immigrants from another world.
Glia 2011, 59:177–187.
35. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell
RA: Blocking TGF-beta-Smad2/3 innate immune signaling mitigates
Alzheimer-like pathology. Nat Med 2008, 14:681–687.
36. Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T: Macrophages in
Alzheimer’s disease: the blood-borne identity. J Neural Transm 2010,
117:961–970.
37. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M,
Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL:
Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in
Alzheimer’s disease. Proc Natl Acad Sci U S A 2003, 100:10032–10037.
38. Ghoshal N, Garcia-Sierra F, Wuu J, Leurgans S, Bennett DA, Berry RW, Binder
LI: Tau conformational changes correspond to impairments of episodic
memory in mild cognitive impairment and Alzheimer’s disease.
Exp Neurol 2002, 177:475–493.
39. Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA,
Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI: Early N-terminal
changes and caspase-6 cleavage of tau in Alzheimer’s disease.
J Neurosci 2004, 24:7895–7902.
40. Yin H, Kuret J: C-terminal truncation modulates both nucleation and
extension phases of tau fibrillization. FEBS Lett 2006, 580:211–215.
41. Basurto-Islas G, Luna-Munoz J, Guillozet-Bongaarts AL, Binder LI, Mena R,
Garcia-Sierra F: Accumulation of aspartic acid421- and glutamic
acid391-cleaved tau in neurofibrillary tangles correlates with progression
in Alzheimer disease. J Neuropathol Exp Neurol 2008, 67:470–483.
42. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, Binder LI:
C-terminal inhibition of tau assembly in vitro and in Alzheimer’s disease.
J Cell Sci 2000, 113:3737–3745.
43. Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R,
Yilmaz Z, Buee L, Brion JP: Early axonopathy preceding neurofibrillary
tangles in mutant tau transgenic mice. Am J Pathol 2007, 171:976–992.
44. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL,
Hyman BT: Caspase activation precedes and leads to tangles. Nature
2010, 464:1201–1204.
45. Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI: Progression of
tau pathology in cholinergic basal forebrain neurons in mild cognitive
impairment and Alzheimer’s disease. Am J Pathol 2011, 179:2533–2550.
46. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM:
Phosphorylation that detaches tau protein from microtubules (Ser262,
Ser214) also protects it against aggregation into Alzheimer paired helical
filaments. Biochemistry 1999, 38:3549–3558.
47. Friedhoff P, von Bergen M, Mandelkow EM, Mandelkow E: Structure of tau
protein and assembly into paired helical filaments. Biochim Biophys Acta
2000, 1502:122–132.
48. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E: Tau protein and tau
aggregation inhibitors. Neuropharmacology 2010, 59:276–289.
49. von Bergen M, Barghorn S, Muller SA, Pickhardt M, Biernat J, Mandelkow
EM, Davies P, Aebi U, Mandelkow E: The core of tau-paired helicalfilaments studied by scanning transmission electron microscopy and
limited proteolysis. Biochemistry 2006, 45:6446–6457.
50. Krishnamurthy PK, Deng Y, Sigurdsson EM: Mechanistic studies of
antibody-mediated clearance of Tau aggregates using an ex vivo brain
slice model. Front Psychiatry 2011, 2:59.
51. Sigurdsson EM: Tau-focused immunotherapy for Alzheimer’s disease and
related tauopathies. Curr Alzheimer Res 2009, 6:446–450.
52. Lim F, Hernandez F, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J: FTDP-17
mutations in tau transgenic mice provoke lysosomal abnormalities and
Tau filaments in forebrain. Mol Cell Neurosci 2001, 18:702–714.
53. Yamada K, Holth JK, Liao F, Stewart FR, Mahan TE, Jiang H, Cirrito JR, Patel
TK, Hochgrafe K, Mandelkow EM, Holtzman DM: Neuronal activity
regulates extracellular tau in vivo. J Exp Med 2014, 211:387–393.
54. Clavaguera F, Grueninger F, Tolnay M: Intercellular transfer of tau
aggregates and spreading of tau pathology: implications for therapeutic
strategies. Neuropharmacology 2014, 76 Pt A:9–15.
doi:10.1186/s12974-014-0152-0
Cite this article as: Selenica et al.: Epitope analysis following active
immunization with tau proteins reveals immunogens implicated in tau
pathogenesis. Journal of Neuroinflammation 2014 11:152.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
